BIOMIND LABS INC. Market Cap ($3.31 Million)
Market Cap & Net Worth: BIOMIND LABS INC. (3XI)
BIOMIND LABS INC. market cap. BIOMIND LABS INC. (F:3XI) has a market capitalization of $3.31 Million (€2.83 Million) as of November 1, 2026. Listed on the F stock exchange, this Germany-based company holds position #29301 globally and #2537 in its home market, demonstrating a -30.48% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying BIOMIND LABS INC.'s stock price €0.04 by its total outstanding shares 77571773 (77.57 Million). Also see BIOMIND LABS INC. (3XI) cash flow conversion for how efficiently the company converts equity into cash flow.
BIOMIND LABS INC. Market Cap History (2021–2026)
BIOMIND LABS INC. market cap history from 2021 to 2026. Data shows change from $83.43 Million to $3.31 Million (-53.39% CAGR). Check BIOMIND LABS INC. (3XI) stock price for real-time trading data and today's change.
BIOMIND LABS INC. Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how BIOMIND LABS INC.'s valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Explore 3XI net assets growth trend to track how rapidly the company is growing its equity base year over year.
Latest Price to Sales (P/S) Ratio
No P/S ratio data available
Latest Price to Earnings (P/E) Ratio
No P/E ratio data available
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| No financial ratio data available | |||||
Competitor Companies of 3XI by Market Capitalization
Companies near BIOMIND LABS INC. in the global market cap rankings as of November 1, 2026. Also see 3XI current and non-current assets for a full breakdown of the balance sheet.
Key companies related to BIOMIND LABS INC. by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #182 globally with a market cap of $130.90 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #371 globally with a market cap of $76.14 Billion USD.
- CSL Ltd (AU:CSL): Ranked #412 globally with a market cap of $68.91 Billion USD ( AU$97.38 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #495 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #182 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.90 Billion | $558.88 |
| #371 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $76.14 Billion | $927.89 |
| #412 | CSL Ltd | AU:CSL | $68.91 Billion | AU$200.73 |
| #495 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $221.72 |
Market Capitalization of BIOMIND LABS INC. (2021–2026)
Market capitalization of BIOMIND LABS INC. from 2021 to today. Between 2021 and today, BIOMIND LABS INC.'s market cap moved from $83.43 Million to $ 3.31 Million, with a yearly change of -53.39%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | €3.31 Million | -46.72% |
| 2025 | €6.21 Million | -75.88% |
| 2024 | €25.76 Million | +14100.00% |
| 2023 | €181.38K | -99.22% |
| 2022 | €23.40 Million | -71.96% |
| 2021 | €83.43 Million | -- |
End of Day Market Cap According to Different Sources
On Oct 31st, 2026 the market cap of BIOMIND LABS INC. was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $3.31 Million USD |
| MoneyControl | $3.31 Million USD |
| MarketWatch | $3.31 Million USD |
| marketcap.company | $3.31 Million USD |
| Reuters | $3.31 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About BIOMIND LABS INC.
Biomind Labs Inc., a biotech research and development company, focuses on developing novel pharmaceutical drugs and nanotech delivery systems for various psychiatric and neurological conditions. The company is developing BMND01, which is in Phase II clinical trials for use in the treatment of depression; BMND08, a 5-Metoxi-N,N-dimethyltryptamine based formulation that is in Phase II clinical tria… Read more